Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. BioLyte Laboratories, LLC
WARNING LETTER
•BioLyte Laboratories, LLC•December 18, 2019

BioLyte Laboratories, LLC – FDA Warning Letter, Dec 18, 2019

Record Details

The FDA inspected BioLyte Laboratories, LLC, from December 9-18, 2019, and February 13, 2020, identifying significant violations of CGMP regulations for finished pharmaceuticals and misbranding regulations for dietary supplements. The firm's drug products, including various silver, pain relief, and magnesium oil products, are deemed adulterated and unapproved new drugs, violating sections 501(a)(2)(B), 505(a), and 301(d) of the FD&C Act. They are also misbranded under section 502.

Key CGMP violations include: 1. Failure to perform adequate laboratory testing for identity and strength of active ingredients in each batch of drug product prior to release (21 CFR 211.165(a)). 2. Failure to conduct identity testing for each component of drug products and validate supplier test analyses (21 CFR 211.84(d)(1) and (2)). 3. Failure to establish a written stability testing program to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).

The products are unapproved new drugs because they lack FDA approval and are not generally recognized as safe and effective (GRASE). Specifically, CBD and magnesium are not recognized active ingredients in applicable monographs or TFMs, and silver-containing

Company
BioLyte Laboratories, LLC
Inspection date
December 18, 2019
Product type
Drugs
Office
Division of Pharmaceutical Quality Operations III
People
  • Art O. Czabaniuk (Program Division Director)
  • Brian W. Garthwaite
View Company Profile

ID · 45eb4a5d-f81a-4182-8f5e-d1d033bb1eea

Violation Codes10
21 CFR 21021 CFR 21121 CFR 10121 CFR 211.165(a)21 CFR 211.84(d)(1)21 CFR 211.84(d)(2)21 CFR 211.166(a)21 CFR 201.12821 CFR 201.10(c)(4)21 CFR 330

Full citation text and observation details available on the Dashboard.

Other documents for BioLyte Laboratories, LLC
  • 483 - 2025-09-12September 12, 2025
  • 483 - 2023-04-24April 24, 2023
  • 483 - 2019-12-18December 18, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore BioLyte Laboratories, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.